Effect of B₄C& Fly ash on the hardness of AMCs. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Group control-after intervention. حسب Nan Tang (642590)

الموضوعات:

Group SFA-before intervention. حسب Nan Tang (642590)

الموضوعات:

Lost cases. حسب Nan Tang (642590)

الموضوعات:

Baseline sociodemographic data and disease-related variables of two groups (n = 105). حسب Nan Tang (642590)

الموضوعات:

Analysis of SAS, SDS, PSQI, and FertiQoL scores. حسب Nan Tang (642590)

الموضوعات:

Regression analysis of the relationship between intervention and anxiety, depression, sleep quality, quality of life, and clinical pregnancy rate. حسب Nan Tang (642590)

الموضوعات:

Group control-before intervention. حسب Nan Tang (642590)

الموضوعات:

Patient satisfaction with SFA intervention(%). حسب Nan Tang (642590)

الموضوعات:

Pre-Experiment. حسب Nan Tang (642590)

الموضوعات:

Between-group comparison of clinical pregnancy rate after intervention(%). حسب Nan Tang (642590)

الموضوعات:

Group SFA-after intervention. حسب Nan Tang (642590)

الموضوعات:

Intervention process of two groups. حسب Nan Tang (642590)

الموضوعات:

S1 File - حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Experimental treatments and groups. حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Primers for RT-qPCR. حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. حسب Kazuyoshi Ohkawa (836847)

الموضوعات: